Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy
BackgroundMetabolic and nutritional status are recognized as prognostic and predictive biomarkers in cancer treatment. However, there is limited research on oligometastatic non-small cell lung cancer (NSCLC) patients undergoing radiotherapy. We aimed to explore the independent and synergistic effect...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2025.1588391/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839645613871857664 |
|---|---|
| author | Zhifei Huang Zhifei Huang Zhifei Huang Zhifei Huang Ziwen Guo Ziwen Guo Ziwen Guo Ziwen Guo Bo Gao Bo Gao Bo Gao Bo Gao Shun Li Shun Li Shun Li Shun Li Yaner Yu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Zelai He Haiyan Chen Haiyan Chen Hao Jiang Hao Jiang Hao Jiang Hao Jiang |
| author_facet | Zhifei Huang Zhifei Huang Zhifei Huang Zhifei Huang Ziwen Guo Ziwen Guo Ziwen Guo Ziwen Guo Bo Gao Bo Gao Bo Gao Bo Gao Shun Li Shun Li Shun Li Shun Li Yaner Yu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Zelai He Haiyan Chen Haiyan Chen Hao Jiang Hao Jiang Hao Jiang Hao Jiang |
| author_sort | Zhifei Huang |
| collection | DOAJ |
| description | BackgroundMetabolic and nutritional status are recognized as prognostic and predictive biomarkers in cancer treatment. However, there is limited research on oligometastatic non-small cell lung cancer (NSCLC) patients undergoing radiotherapy. We aimed to explore the independent and synergistic effects of body composition and immune-nutritional status on survival outcomes in these patients.MethodsPatients with oligometastatic NSCLC who underwent radiotherapy between 2017 and 2022 were retrospectively included. The evaluated outcomes were overall survival (OS) and progression-free survival (PFS). The skeletal muscle index (SMI), subcutaneous fat index (SFI), and pericardial fat index (PFI) were obtained using computed tomography (CT) and normalized by height squared. Laboratory biomarkers were utilized to assess immune-nutritional status. Univariate chi-square tests and multivariate logistic regression analyses were employed to determine correlations between hematological parameters and body composition. We conducted K-M analyses, along with univariate and multivariate Cox regression analyses to evaluate survival outcomes.Results102 patients [mean age 61.44 years, 51 males (50%)] were included. Compared to non-responders, responders exhibited a significantly lower prevalence of sarcopenia (44.93 vs. 55.07%, P = 0.007) and demonstrated relatively better immune-nutritional scores. Logistic regression analyses revealed that a low Prognostic Nutritional Index (PNI) was a risk factor for SMI, SFI, and PFI. Multivariate Cox analyses revealed that C reactive protein-to-albumin ratio (CAR) (HR = 0.26; 95% CI 0.11–0.61; P = 0.002) and PFI (HR = 2.73; 95% CI 1.06–7.01; P = 0.037) were predictive factors for OS. CAR (HR = 0.34, P = 0.001) and SFI (HR = 1.82, P = 0.049) were independent prognostic markers for PFS. K-M analyses indicated that the group with high PNI and high SFI exhibited markedly improved OS and PFS, as well as the one with high PNI and without sarcopenia (P < 0.001).ConclusionAmong oligometastatic NSCLC patients receiving radiotherapy, higher skeletal muscle and fat content, along with better immune-nutritional status, correlated with improved survival outcomes. |
| format | Article |
| id | doaj-art-cbccff93f7a24e6b8d3d64b3efc0b0f7 |
| institution | Matheson Library |
| issn | 2296-861X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj-art-cbccff93f7a24e6b8d3d64b3efc0b0f72025-07-01T14:12:16ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2025-07-011210.3389/fnut.2025.15883911588391Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapyZhifei Huang0Zhifei Huang1Zhifei Huang2Zhifei Huang3Ziwen Guo4Ziwen Guo5Ziwen Guo6Ziwen Guo7Bo Gao8Bo Gao9Bo Gao10Bo Gao11Shun Li12Shun Li13Shun Li14Shun Li15Yaner Yu16Shuangqiu Zhu17Shuangqiu Zhu18Shuangqiu Zhu19Shuangqiu Zhu20Zelai He21Haiyan Chen22Haiyan Chen23Hao Jiang24Hao Jiang25Hao Jiang26Hao Jiang27Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaDepartment of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaAnhui Hospital, The Second Affiliated Hospital of Zhejiang University School of Medicine, Bengbu, Anhui, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, ChinaJoint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, ChinaBackgroundMetabolic and nutritional status are recognized as prognostic and predictive biomarkers in cancer treatment. However, there is limited research on oligometastatic non-small cell lung cancer (NSCLC) patients undergoing radiotherapy. We aimed to explore the independent and synergistic effects of body composition and immune-nutritional status on survival outcomes in these patients.MethodsPatients with oligometastatic NSCLC who underwent radiotherapy between 2017 and 2022 were retrospectively included. The evaluated outcomes were overall survival (OS) and progression-free survival (PFS). The skeletal muscle index (SMI), subcutaneous fat index (SFI), and pericardial fat index (PFI) were obtained using computed tomography (CT) and normalized by height squared. Laboratory biomarkers were utilized to assess immune-nutritional status. Univariate chi-square tests and multivariate logistic regression analyses were employed to determine correlations between hematological parameters and body composition. We conducted K-M analyses, along with univariate and multivariate Cox regression analyses to evaluate survival outcomes.Results102 patients [mean age 61.44 years, 51 males (50%)] were included. Compared to non-responders, responders exhibited a significantly lower prevalence of sarcopenia (44.93 vs. 55.07%, P = 0.007) and demonstrated relatively better immune-nutritional scores. Logistic regression analyses revealed that a low Prognostic Nutritional Index (PNI) was a risk factor for SMI, SFI, and PFI. Multivariate Cox analyses revealed that C reactive protein-to-albumin ratio (CAR) (HR = 0.26; 95% CI 0.11–0.61; P = 0.002) and PFI (HR = 2.73; 95% CI 1.06–7.01; P = 0.037) were predictive factors for OS. CAR (HR = 0.34, P = 0.001) and SFI (HR = 1.82, P = 0.049) were independent prognostic markers for PFS. K-M analyses indicated that the group with high PNI and high SFI exhibited markedly improved OS and PFS, as well as the one with high PNI and without sarcopenia (P < 0.001).ConclusionAmong oligometastatic NSCLC patients receiving radiotherapy, higher skeletal muscle and fat content, along with better immune-nutritional status, correlated with improved survival outcomes.https://www.frontiersin.org/articles/10.3389/fnut.2025.1588391/fullbody compositionimmune-nutritional scoresoligometastasisNSCLCradiotherapy |
| spellingShingle | Zhifei Huang Zhifei Huang Zhifei Huang Zhifei Huang Ziwen Guo Ziwen Guo Ziwen Guo Ziwen Guo Bo Gao Bo Gao Bo Gao Bo Gao Shun Li Shun Li Shun Li Shun Li Yaner Yu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Shuangqiu Zhu Zelai He Haiyan Chen Haiyan Chen Hao Jiang Hao Jiang Hao Jiang Hao Jiang Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy Frontiers in Nutrition body composition immune-nutritional scores oligometastasis NSCLC radiotherapy |
| title | Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy |
| title_full | Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy |
| title_fullStr | Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy |
| title_full_unstemmed | Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy |
| title_short | Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy |
| title_sort | prognostic impact of body composition and immune nutritional status in oligometastatic nsclc patients receiving radiotherapy |
| topic | body composition immune-nutritional scores oligometastasis NSCLC radiotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2025.1588391/full |
| work_keys_str_mv | AT zhifeihuang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT zhifeihuang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT zhifeihuang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT zhifeihuang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT ziwenguo prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT ziwenguo prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT ziwenguo prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT ziwenguo prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT bogao prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT bogao prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT bogao prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT bogao prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shunli prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shunli prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shunli prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shunli prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT yaneryu prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shuangqiuzhu prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shuangqiuzhu prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shuangqiuzhu prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT shuangqiuzhu prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT zelaihe prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haiyanchen prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haiyanchen prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haojiang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haojiang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haojiang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy AT haojiang prognosticimpactofbodycompositionandimmunenutritionalstatusinoligometastaticnsclcpatientsreceivingradiotherapy |